Terms: = Thyroid cancer AND RAF1, Raf-1, 5894, P04049, ENSG00000132155, c-Raf, CRAF AND Prognosis
6 results:
1. Characterization of the genomic alterations in poorly differentiated thyroid cancer.
Lee Y; Moon S; Seok JY; Lee JH; Nam S; Chung YS
Sci Rep; 2023 Nov; 13(1):19154. PubMed ID: 37932340
[TBL] [Abstract] [Full Text] [Related]
2. RREB1 promotes the development of parafollicular carcinogenesis through the Ras-raf-1-ELK3 signaling pathway.
Ma S; Wang H; Li W; Yan Z; Luo X; Lu P
Nucleosides Nucleotides Nucleic Acids; 2022; 41(10):972-981. PubMed ID: 35737446
[TBL] [Abstract] [Full Text] [Related]
3. Molecular Profiling of Follicular Variant of Papillary thyroid cancer.
Spirina LV; Chizhevskaya SY; Kondakova IV
Bull Exp Biol Med; 2020 May; 169(1):85-88. PubMed ID: 32495172
[TBL] [Abstract] [Full Text] [Related]
4. LncRNA LINC00460 promotes the papillary thyroid cancer progression by regulating the LINC00460/miR-485-5p/raf1 axis.
Li G; Kong Q
Biol Res; 2019 Dec; 52(1):61. PubMed ID: 31870440
[TBL] [Abstract] [Full Text] [Related]
5. Screening for thyroid cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Lin JS; Bowles EJA; Williams SB; Morrison CC
JAMA; 2017 May; 317(18):1888-1903. PubMed ID: 28492904
[TBL] [Abstract] [Full Text] [Related]
6. Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated thyroid cancer.
Wei WJ; Sun ZK; Shen CT; Song HJ; Zhang XY; Qiu ZL; Luo QY
Theranostics; 2017; 7(4):987-1001. PubMed ID: 28382170
[TBL] [Abstract] [Full Text] [Related]
